

FES PET/CT is included as an imaging option for systemic staging of ER+ recurrent / stage IV (M1) disease in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer



Imaging for Systemic Staging	Chest diagnostic CT	± contrast
	Abdominal ± pelvic diagnostic CT or MRI	+ contrast or + contrast, respectively
	Brain MRI	+ contrast if suspicious CNS symptoms
	Spine MRI	+ contrast if back pain or symptoms of cord compression
	Bone scan or sodium fluoride PET/CT	Listed as Category 2B (Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate)
	PET/CT FDG or FES	Useful in certain circumstances: FDG PET/CT Consider FES PET/CT for ER-positive disease and lobular histology
	X-rays	Of symptomatic bones and long and weight-bearing bones abnormal on bone scan

NCCN Guidelines®

- Useful in certain circumstances: FDG PET/CT (**consider FES PET/CT for ER-positive disease and lobular histology**)
- Unless otherwise noted, all recommendations are NCCN **Category 2A**
- **Category 2A:** Based upon lower-level evidence, there is uniform NCCN consensus (≥ 85% support of the Panel) that the intervention is appropriate.

NCCN makes no warranties of any kind whatsoever regarding its content, use, or application and disclaims any responsibility for how its content is applied or use, in any way.
 References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.1.2025. © 2025 National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed February 27, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org.